NCT00465972

Brief Summary

This study is designed to evaluate the efficacy of two commonly prescribed sleep aids for use in patients who are HIV positive and suffer from insomnia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for phase_4 hiv-infections

Timeline
Completed

Started Mar 2007

Typical duration for phase_4 hiv-infections

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2007

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

April 25, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 27, 2007

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2010

Completed
3 years until next milestone

Results Posted

Study results publicly available

July 30, 2013

Completed
Last Updated

July 30, 2013

Status Verified

May 1, 2013

Enrollment Period

3.4 years

First QC Date

April 25, 2007

Results QC Date

December 12, 2012

Last Update Submit

July 26, 2013

Conditions

Keywords

HIVInsomniaCytokinesAdherence

Outcome Measures

Primary Outcomes (1)

  • Response: Change in Insomnia Severity Rating Scale at 3 Months.

    Insomnia Severity Index; It is a measure of Insomnia Severity; A higher number indicates greater severity of insomnia. Range of possible score totals is 0-28.

    Baseline and 3 months

Secondary Outcomes (1)

  • Change in Piper Fatigue Scale at 3 Months

    Baseline and 3 months

Study Arms (3)

Placebo

PLACEBO COMPARATOR

Placebo

Drug: Placebo

2

ACTIVE COMPARATOR

Doxepin

Drug: Doxepin

3

ACTIVE COMPARATOR

Temazepam

Drug: Temazepam

Interventions

Doxepin 10 mg po nightly x duration of study length OR Temazepam 15 mg po nightly x duration of study length OR Placebo nightly x duration of study length

2

Temazepam capsule 15 mg po nightly x duration of study

3

Placebo capsule nightly for duration of study

Placebo

Eligibility Criteria

Age18 Years - 69 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Insomnia
  • HIV Seropositive
  • Stable HIV Disease

You may not qualify if:

  • Other psychiatric illnesses
  • Unstable HIV disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Duke University Medical Center

Durham, North Carolina, 27710, United States

Location

Related Publications (2)

  • Reid S, Dwyer J. Insomnia in HIV infection: a systematic review of prevalence, correlates, and management. Psychosom Med. 2005 Mar-Apr;67(2):260-9. doi: 10.1097/01.psy.0000151771.46127.df.

    PMID: 15784792BACKGROUND
  • Low Y, Preud'homme X, Goforth HW, Omonuwa T, Krystal AD. The association of fatigue with depression and insomnia in HIV-seropositive patients: a pilot study. Sleep. 2011 Dec 1;34(12):1723-6. doi: 10.5665/sleep.1446.

MeSH Terms

Conditions

HIV InfectionsSleep Initiation and Maintenance Disorders

Interventions

DoxepinTemazepam

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesMental Disorders

Intervention Hierarchy (Ancestors)

OxepinsEthers, CyclicEthersOrganic ChemicalsDibenzoxepinsHeterocyclic Compounds, 3-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsBenzodiazepinonesBenzodiazepinesBenzazepinesHeterocyclic Compounds, 2-Ring

Results Point of Contact

Title
Andrew Krystal, MD, MS, Professor of Psychiatry and Behavioral Sciences
Organization
Duke University School of Medicine

Study Officials

  • Andrew D Krystal, MD

    Duke University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 25, 2007

First Posted

April 27, 2007

Study Start

March 1, 2007

Primary Completion

August 1, 2010

Study Completion

August 1, 2010

Last Updated

July 30, 2013

Results First Posted

July 30, 2013

Record last verified: 2013-05

Locations